Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
View/ Open
Published version
Embargoed until: 5555-01-01
Embargoed until: 5555-01-01
Volume
17
Pagination
917 - 927
DOI
10.1016/S1470-2045(16)30107-3
Journal
LANCET ONCOLOGY
Issue
ISSN
1470-2045